Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study Among Healthcare Workers in Turkey

Investor logo

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

RIAD Abanoub SAGIROGLU Derya ÜSTÜN Batuhan POKORNÁ Andrea KLUGAROVÁ Jitka ATTIA Sameh KLUGAR Miloslav

Year of publication 2021
Type Article in Periodical
Magazine / Source Journal of Clinical Medicine
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.mdpi.com/2077-0383/10/12/2629
Doi http://dx.doi.org/10.3390/jcm10122629
Keywords COVID-19; drug-related side effects and adverse reactions; health personnel; mass vaccination; prevalence
Description Background: COVIC-19 vaccine hesitancy is a serious threat to mass vaccination strategies that need to be accelerated currently for achieving a substantial level of community immunity. Independent (non-sponsored) studies have a great potential to enhance public confidence in vaccines and accelerate their uptake process. Methods: A nationwide cross-sectional study for the side effects (SE) of CoronaVac was carried out in February 2021 among Turkish healthcare workers who got recently vaccinated. The questionnaire inquired about local and systemic SEs that occurred in the short-term, within four weeks, following vaccination. Findings: A total of 780 healthcare workers were included in this study; 62.5% of them experienced at least one SE. Injection site pain (41.5%) was the most common local SE, while fatigue (23.6%), headache (18.7%), muscle pain (11.2%) and joint pain (5.9%) were the common systemic SE. Female healthcare workers (67.9%) were significantly more affected by local and systemic SEs than male colleagues (51.4%). Younger age, previous infection, and compromised health status (chronic illnesses and regular medicines uptake) can be associated with an increased risk of CoronaVac SEs. Interpretation: The independent research shows a higher prevalence of CoronaVac SEs than what is reported by phase 1 – 3 clinical trials. In general, the results of this study confirm the overall safety of CoronaVac and suggest potential risk factors for its SEs. Gender-based differences and SEs distribution among age groups are worth further investigation.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.